Research ReportAn evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat
Introduction
Administration of the chemotherapeutic agent paclitaxel can induce a dose-dependent peripheral sensory neuropathy in a subset of patients receiving this therapy for breast, ovarian, and non-small cell lung cancer (Lee and Swain, 2006, Mielke et al., 2006). Following administration of paclitaxel patients may experience a range of positive sensory symptoms including spontaneous tingling, burning pain, joint and muscle pain (Postma et al., 1995, Quasthoff and Hartung, 2002, Dougherty et al., 2004) that often occur in the distal extremities in a “glove and stocking” distribution. These symptoms may increase in severity and be accompanied by sensory deficits including numbness, loss of vibratory sensation, decreased deep tendon reflexes and decreased proprioceptive abilities (Rowinsky et al., 1993, Postma et al., 1995). In many patients, these symptoms spontaneously resolve following discontinuation of therapy, while in others they may persist for weeks to a lifetime (Pignata et al., 2006). Despite the widespread incidence of paclitaxel-induced peripheral neuropathy (PIPN) and increasing use of paclitaxel in the treatment of various tumors (Giordano et al., 2006), there is currently no accepted standard of care to prevent/treat the pain or sensory dysfunction associated with this condition. The lack of standard treatment strategies is in part due to a lack of information regarding the cellular mechanisms responsible for the development of PIPN.
Recently, using a previously characterized model of PIPN (Cliffer et al., 1998), we reported pathological features in the dorsal root ganglia (DRG) and sciatic nerve 10 days following intravenous administration of paclitaxel in rats (Peters et al., 2007). This cellular pathology was accompanied by behavioral changes indicative of a sensory neuropathy including cold and mechanical allodynia as well as behavioral deficits in coordination (Peters et al., 2007). Examination of sensory ganglia at multiple levels of the neuroaxis revealed that the cellular pathology occurred in a length-dependent manner (Jimenez-Andrade et al., 2006) similar to the pattern of symptoms observed in patients treated with taxanes. What remains unknown is the time course of the evolution of cellular events that occur following intravenous paclitaxel administration. In the current study, we examined the time course of changes in markers of cell injury/regeneration (ATF3), activation of satellite cells (GFAP), macrophage hypertrophy and hyperplasia (CD68) and microglial and astrocyte activation/hypertrophy (CD11b and GFAP, respectively) within the DRG, sciatic nerve, and spinal cord following intravenous administration of paclitaxel in the rat.
Section snippets
Time course of neuronal and non-neuronal ATF3 expression in the DRG of paclitaxel-treated rats
In the current study, we examined immunohistochemically the levels of activating transcription factor 3 (ATF3) in the DRG of rats that received intravenous paclitaxel or vehicle. We administered two infusions of paclitaxel at a dose of 18 mg/kg (day 0 and day 3; 36 mg/kg cumulative dose). We examined ATF3 expression in fourth lumbar (L4) DRG at days 1, 4, 6 and 10 following the first infusion. The percentage of ATF3-immunoreactivity (IR) neuronal profiles significantly increased in
Impact of intravenous paclitaxel on sensory neurons in the DRG
PIPN is a continuing challenge in the treatment of cancer as it can have a significant impact on cancer patient's quality of life and survivorship (Mantyh, 2006). Despite the widespread incidence of this neuropathy, the cellular mechanisms responsible for its development are largely unknown. In the present study, the up-regulation of ATF3 by a subset of small, medium and large sensory neurons was the first cellular marker of those we examined to show a change following intravenous infusion of
Animals and drugs
All procedures were approved by the Institutional Animal Care and Use Committee at the University of Minnesota. Adult male Sprague Dawley rats (250–275 g; Harlan, Indianapolis, IN) were used in the present study. Paclitaxel was formulated by dissolving paclitaxel (Eton Bioscience, San Diego, CA) in Cremophor EL and dehydrated ethanol (1:1) to make a stock solution of 12 mg/ml. Prior to administration, the paclitaxel solution was further diluted with sterile saline (1:3). The paclitaxel solution
Acknowledgments
This work was supported by National Institutes of Health grants (NS23970, NS048021), a Merit Review from the Veterans Administration, and NIH Musculoskeletal Training grant T32 AR 050938-01.
References (67)
- et al.
Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol
Exp. Neurol.
(1995) - et al.
Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy
Pain
(2000) - et al.
Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients
Pain
(2004) - et al.
GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801
Exp. Neurol.
(1994) Satellite glial cells in sensory ganglia: from form to function
Brain Res. Brain Res. Rev.
(2005)- et al.
Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat
Neuroscience
(2002) - et al.
Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat
Neurosci. Lett.
(2006) - et al.
Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy
Peptides
(1990) - et al.
Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury
Neuroscience
(2003) - et al.
Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes
Eur. J. Cancer
(2006)
Macrophage response to peripheral nerve injury: the quantitative contribution of resident and hematogenous macrophages
Lab. Invest.
Reduced hyperalgesia in nerve-injured WLD mice: relationship to nerve fiber phagocytosis, axonal degeneration, and regeneration in normal mice
Exp. Neurol.
Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1–13) or MK-801 in a nerve–ligation model of peripheral neuropathy
Pain
Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats
Pain
Macrophages and nerve regeneration
Curr. Opin. Neurobiol.
Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats
Eur. J. Cancer
Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain
Exp. Neurol.
Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells
Exp. Neurol.
Paclitaxel-induced neuropathy
Ann. Oncol.
The transcription factor ATF-3 promotes neurite outgrowth
Mol. Cell. Neurosci.
GFAP immunoreactivity in trigeminal ganglion satellite cells after tooth injury in rats
Exp. Neurol.
Distribution of S-100 protein outside the central nervous system
Brain Res.
Neuropathic pain and spinal microglia: a big problem from molecules in “small” glia
Trends Neurosci.
Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury
Mol. Cell. Neurosci.
Differential regulation of P2X(3) mRNA expression by peripheral nerve injury in intact and injured neurons in the rat sensory ganglia
Pain
Glial cell line-derived neurotrophic factor normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain
Neuroscience
Glial activation: a driving force for pathological pain [Review]
Trends Neurosci.
Satellite cells surrounding axotomised rat dorsal root ganglion cells increase expression of a GFAP-like protein
Neurosci. Lett.
Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia
Neuroscience
Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2
Proc. Natl. Acad. Sci. U. S. A.
Glial responses to synaptic damage and plasticity
J. Neurosci. Res.
NGF and GDNF ameliorate the increase in ATF3 expression which occurs in dorsal root ganglion cells in response to peripheral nerve injury
Eur. J. Neurosci.
Sympathetic and afferent somata projecting in hindlimb nerves and the anatomical organization of the lumbar sympathetic nervous system of the rat
J. Comp. Neurol.
Cited by (148)
Small Synthetic Hyaluronan Disaccharide BIS014 Mitigates Neuropathic Pain in Mice
2023, Journal of PainRole of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy
2022, Journal of Pharmacological SciencesNeuropathic pain modeling: Focus on synaptic and ion channel mechanisms
2021, Progress in NeurobiologyCitation Excerpt :NP results in dose reduction or early discontinuation of treatment, which may impact cancer re-emergence and patient survival. Interestingly, different classes of chemotherapeutics are used to induce NP in animals, such as cisplatin (Tredici et al., 1998; Bianchi et al., 2007), vincristine (Gottschalk et al., 1968) (Sweitzer et al., 2006) and taxanes (Peters et al., 2007). As reported by Ta and colleagues (Ta et al., 2009), mice receiving cumulative doses of cisplatin or oxaliplatin demonstrated mechanical allodynia, and hot and cold hyperalgesia in hind paws and tail.
Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes
2021, Biomedicine and Pharmacotherapy